Alimera Down So Much That Now is a Good Time to Buy; Citi (ALIM)

Citi analyst Amit Bhalla reiterated a Buy rating for Alimera Sciences

today. Alimera is a biopharmacist specializing in prescription ophthalmic pharmaceuticals. ALIM is down 37% since its IPO on April 23rd, 2010, compared to -14% for the S&P. Citi thinks that this represents an excellent buying opportunity. Citi gave the following catalysts for Alimera's growth: "(1) FDA granting the NDA Iluvien Priority Review (2) we expect the company to file the Iluvien Phase III data with European regulatory authorities in the coming weeks leading to a 2011 approval (3) we believe the FDA will approve Iluvien in 4Q10 leading to a 1Q11 US product launch." Alimera received a price target of $15.00 from Citi. Shares are currently trading at $7.04. Learn how to find the best

for free.